Status:
WITHDRAWN
Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
Lead Sponsor:
Dr. Christopher Lambers
Collaborating Sponsors:
Clinical Trials Coordination Centre, Medical University of Vienna
Conditions:
Idiopathic Pulmonary Fibrosis
Lung Transplant; Complications
Eligibility:
All Genders
40-70 years
Brief Summary
The diagnosis of idiopathic pulmonary fibrosis (IPF) is currently one of the most common diagnoses for patients under evaluation for lung transplantation. In recent years, an absolute increase in prev...
Eligibility Criteria
Inclusion
- For Pirfenidone Group
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study
- mild to moderate idiopathic pulmonary fibrosis (IPF).
- Current or intended treatment with Pirfenidone
- Diagnosis of Interstitial Lung disease
- Evaluation for Lung Transplantation
- Age 40-70
- For Control Group
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study
- mild to moderate idiopathic pulmonary fibrosis (IPF).
- Diagnosis of Interstitial Lung disease
- Evaluation for Lung Transplantation
- Age 40-70
Exclusion
- For Pirfenidone Group
- Other lung diseases (such as cystic fibrosis, COPD)
- Infection with Hepatitis C,
- Liver cirrhosis CHILD C
- Coronary heart disease (3VD)
- For Control Group
- Other lung diseases (such as cystic fibrosis, COPD)
- Infection with Hepatitis C,
- Liver cirrhosis CHILD C
- Coronary heart disease (3VD)
Key Trial Info
Start Date :
October 29 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 2 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03258801
Start Date
October 29 2018
End Date
December 2 2019
Last Update
January 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna, Department of Surgery
Vienna, Austria, 1090